Pediatric Hematology Oncology Journal

Official Journal of PHO Chapter of Indian Academy of Pediatrics

[Pediatric Hematology Oncology Journal @PHOJournal]

When one rare tumor wasn’t rare enough, this toddler said 'Let’s make it a case report'
Synchronous ERMS + ACC + germline CBL mutation = genetics keeping pediatric oncology on its toes.
Moral: If a kid brings two tumors to clinic, always invite genetics to the party #GeneticsWins

[Pediatric Hematology Oncology Journal @PHOJournal]

BRAF V600E mutations. Nanoparticle-based delivery of targeted
agents, like anti-BCL2 or cytokine inhibitors, represents an emerging therapeutic strategy. Have you noticed this phenomenon in your practice? Give your inputs in comments #pediatriclch #langerhanscellhistiocytosis

[Pediatric Hematology Oncology Journal @PHOJournal]

This systematic review by Dana Ashkenazi Lustig and colleagues from Israel speaks about the spontaneous resolution of LCH lesions. Proposed mechanisms include biopsy-induced inflammatory
system modulation, apoptosis via the Fas/Fas-L pathway, & disruption of the MAPK signalling

[Pediatric Hematology Oncology Journal @PHOJournal]

These findings highlight the importance of
regular monitoring of height & weight during & after therapy. 
Future prospective studies incorporating body composition assessments  may provide further insight into sarcopenic obesity & long-term metabolic risks in this population

[Pediatric Hematology Oncology Journal @PHOJournal]

Krisha Savla and colleagues from Tata Memorial Hospital, Mumbai have described their findings about the nutritional status of children with acute leukemias receiving chemotherapy at their centre. Details of the findings in comments.

[Pediatric Hematology Oncology Journal @PHOJournal]

In this cohort, 37.5 % of children classified as malnourished.
At end of Rx, 5.3 % were severely & 22.6 % 
were moderately malnourished, 8.2 % were overweight & 6.7 %
were obese 
Improvement in the status could be attributed to effective nutritional interventions, supportive care

[Pediatric Hematology Oncology Journal @PHOJournal]

https://t.co/8gLHkpFr8G

This interesting article written by Maya Et al describes the diagnostic algorithm in CNS leukemias, CNS directed therapy in ALL, management of CNS disease at relapse, role of newer agents and immunotherapies, CNS directed treatment in ALL and AML.

[Pediatric Hematology Oncology Journal @PHOJournal]

@Wisdom_HQ This is just click bait to be solved by a (moderately) intelligent 7th or 8th grader -- 18 i.e. 3 × (3+3)

[Pediatric Hematology Oncology Journal @PHOJournal]

@drgargidas @IJPJOURNAL Congrats! It is always a great sense of achievement when your thesis gets published! 😊

[Pediatric Hematology Oncology Journal @PHOJournal]

@kidzcancerdoc amazing to think this was only 15 years ago, how awareness is changing in India, but there are now gaps to fill in support for physicians, especially in smaller centers... #childhoodcancer #India #mapping #icci #cankids #pediatriconcology

[Pediatric Hematology Oncology Journal @PHOJournal]

@kidzcancerdoc amazing to think this was only 15 years ago, how awareness is changing in India, but there are now gaps to fill in support for physicians, especially in smaller centers... #childhoodcancer #India #mapping #icci #cankids #pediatriconcology

[Pediatric Hematology Oncology Journal @PHOJournal]

Good morning. Catch us live at the most anticipated event of the year PHOCON 2025!

[Pediatric Hematology Oncology Journal @PHOJournal]

Read this with a report on triple negative thrombocytosis (apparently group 4) in 2025 issue of PHOJ #thrombocytosis #children #PHOJ

[Dr. Chokri Ben Lamine @abouabdrahman0]

TNT (Triple-Negative Thrombocytosis) Treatment Algorithm —
Proposed by BJHaem, Godfrey et al. — shown at the 3rd Kuwait Hematology Conference

🧬 First question: Clonal or non-clonal?
🔍 Second question: Megakaryocyte atypia or not?
➡️ These 2 answers place every patient into 1 of 4 treatment pathways.

⸻

🟥 1) Clonal marker + Megakaryocyte atypia

Triple-Negative ET with clonal marker (cTNT-ET / ITAM-C)
• Age ≥60 or refractory symptoms or cardiovascular RFs → Aspirin if no bleeding risk
• Age ≥60, prior vascular event, persistent Plt ≥1500×10⁹/L, or refractory symptoms → Consider cytoreduction
• Monitor for evolution toward PMF/MDS/other MPN

⸻

🟧 2) Non-clonal + Megakaryocyte atypia

ITAM (Idiopathic thrombocytosis with atypical megakaryocytes / TN-ET without clonal markers)
• Age ≥60, symptoms, or CV risk → Consider aspirin
• Age ≥60, prior vascular event, Plt ≥1500×10⁹/L, or multiple CV RFs → Consider cytoreduction
• Monitor carefully for transformation; marrow should be repeated if phenotype changes

⸻

🟦 3) Clonal marker + No megakaryocyte atypia

CTUS (Clonal thrombocytosis of undetermined significance)
• Age ≥60 or symptoms or CV RFs → Could consider cytoreduction (case-by-case)
• Aspirin can be considered depending on risk profile and Plt count
• Monitor for evolution to ET/MPN

⸻

🟩 4) Non-clonal + No megakaryocyte atypia

ITUS (Idiopathic thrombocytosis of undetermined significance)
• Usually benign course
• Annual FBC monitoring
• Aspirin only if another indication (e.g., CV risk)
• Cytoreduction not recommended

⸻

Key Factors That Determine Treatment

1️⃣ Clonal or non-clonal?
2️⃣ Megakaryocyte atypia present or absent?
3️⃣ Age ≥60?
4️⃣ Symptoms?
5️⃣ Thrombosis history?
6️⃣ Cardiovascular risk factors?
7️⃣ Platelet count?

⸻

#MPN #TNT #TripleNegativeET #ET #CTUS #ITUS #Thrombocytosis #Hematology #NGS #KuwaitHematologyConference #SOHO25 #EmiratesHematologySociety

[Pediatric Hematology Oncology Journal @PHOJournal]

A plea for clinical skills! #PHOJ #physiciantraining #NEJM

[NEJM @NEJM]

Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it.

Read the review “Strategies to Reinvigorate the Bedside Clinical Encounter,” the latest in the Medical Education series, by Brian T. Garibaldi, MD, MEHP, and Stephen W. Russell, MD, from @NUFeinbergMed and the University of Alabama at Birmingham (@UABNews): https://t.co/7IF47hAwzR

[Pediatric Hematology Oncology Journal @PHOJournal]

A deeper dive into NK cell based therapies #PHOJ #NKcells #CancerResearch

[Cancer Cell @Cancer_Cell]

Rewiring natural killer cells for next-generation cancer therapies https://t.co/WRz1HP0qEt

[Dr. Patrick Hwu @PatrickHwuMD]

#ScienceSaturday

❓ What controls whether T cells keep fighting or get tired?

➡️ A recent study in Nature Immunology reveals that a protein called SATB1 acts like a “brake” on CD8 T cells, the immune system’s cancer-fighting soldiers.

➡️ During chronic infections or #cancer, T cells can become exhausted over time. This research shows that SATB1 controls how fast T cells multiply and how strongly they attack tumors. When SATB1 levels are high, T cells stay balanced but may hold back their attack. When SATB1 is removed, T cells expand faster and fight harder, especially when combined with immunotherapy, though they may tire sooner.

➡️ Importantly, blocking #SATB1 improved tumor control and boosted the power of checkpoint inhibitors in preclinical models, suggesting a promising new strategy to enhance cancer immunotherapy.

🌟 Congratulations to the study authors at the University of Melbourne, Peter Doherty Institute, University Hospital Bonn, Peter MacCallum Cancer Center, and collaborators for deepening our understanding of T cell biology and uncovering a potential way to make immunotherapies even more effective. @UniMelb @TheDohertyInst @UniklinikBonn @PeterMacCC @NaturePortfolio

🔗 Read more: https://t.co/VIv9VjgAqg

[Pediatric Hematology Oncology Journal @PHOJournal]

@Cancer_Cell An interesting insight as to how bone mets stay protected!

[Pediatric Hematology Oncology Journal @PHOJournal]

@Cancer_Cell An interesting insight as to how bone mets stay protected!

[Cancer Cell @Cancer_Cell]

CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases https://t.co/OMVujtbvQ1

[Pediatric Hematology Oncology Journal @PHOJournal]

https://t.co/AN0R600oyM